PL3383385T3 - Schematy dawkowania melflufenu w nowotworze złośliwym - Google Patents

Schematy dawkowania melflufenu w nowotworze złośliwym

Info

Publication number
PL3383385T3
PL3383385T3 PL16805792T PL16805792T PL3383385T3 PL 3383385 T3 PL3383385 T3 PL 3383385T3 PL 16805792 T PL16805792 T PL 16805792T PL 16805792 T PL16805792 T PL 16805792T PL 3383385 T3 PL3383385 T3 PL 3383385T3
Authority
PL
Poland
Prior art keywords
melflufen
dosing regimens
malignant neoplasm
neoplasm
malignant
Prior art date
Application number
PL16805792T
Other languages
English (en)
Other versions
PL3383385T5 (pl
Inventor
Jakob LINDBERG
Original Assignee
Oncopeptides Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55177548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3383385(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncopeptides Ab filed Critical Oncopeptides Ab
Publication of PL3383385T3 publication Critical patent/PL3383385T3/pl
Publication of PL3383385T5 publication Critical patent/PL3383385T5/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PL16805792.5T 2015-12-01 2016-12-01 Schematy dawkowania melflufenu w nowotworze złośliwym PL3383385T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1521217.8A GB201521217D0 (en) 2015-12-01 2015-12-01 Dosage regimens
PCT/EP2016/079511 WO2017093443A1 (en) 2015-12-01 2016-12-01 Melflufen dosage regimens for cancer
EP16805792.5A EP3383385B2 (en) 2015-12-01 2016-12-01 Melflufen dosage regimens for cancer

Publications (2)

Publication Number Publication Date
PL3383385T3 true PL3383385T3 (pl) 2021-05-04
PL3383385T5 PL3383385T5 (pl) 2023-12-18

Family

ID=55177548

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16805792.5T PL3383385T5 (pl) 2015-12-01 2016-12-01 Schematy dawkowania melflufenu w nowotworze złośliwym

Country Status (27)

Country Link
US (3) US20180369141A1 (pl)
EP (3) EP3903777A1 (pl)
JP (2) JP6878431B2 (pl)
KR (2) KR102279629B1 (pl)
CN (1) CN108289876A (pl)
AU (2) AU2016363591B2 (pl)
BR (1) BR112018010012A8 (pl)
CA (1) CA3003102C (pl)
CY (1) CY1123469T1 (pl)
DK (1) DK3383385T4 (pl)
ES (1) ES2828033T5 (pl)
FI (1) FI3383385T4 (pl)
GB (1) GB201521217D0 (pl)
HR (1) HRP20201632T4 (pl)
HU (1) HUE051525T2 (pl)
IL (2) IL301019B2 (pl)
LT (1) LT3383385T (pl)
MX (2) MX384724B (pl)
PL (1) PL3383385T5 (pl)
PT (1) PT3383385T (pl)
RS (1) RS60986B2 (pl)
RU (2) RU2020134307A (pl)
SG (1) SG11201803551YA (pl)
SI (1) SI3383385T2 (pl)
SM (1) SMT202000567T1 (pl)
WO (1) WO2017093443A1 (pl)
ZA (2) ZA201802816B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12152087B2 (en) * 2018-10-18 2024-11-26 Oncopeptides Innovation Ab Deuterated melflufen compounds
JP7712206B2 (ja) * 2019-01-28 2025-07-23 サノフィ-アベンティス・ユー・エス・エルエルシー 多発性骨髄腫の処置方法
WO2020201542A1 (en) * 2019-04-03 2020-10-08 Oncopeptides Ab Treatment of al amyloidosis with melflufen
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
WO2021053185A1 (en) * 2019-09-20 2021-03-25 Oncopeptides Ab Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma
SE544998C2 (en) * 2021-01-13 2023-02-21 Bkmdcl Ab Peptide conjugates of melphalan for the treatment of cancer
JP2024524552A (ja) * 2021-07-08 2024-07-05 オンコペプティデス エービー 多発性骨髄腫の治療に使用するためのメルフルフェン

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) * 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
DK2701720T3 (en) 2011-04-28 2017-10-09 Oncopeptides Ab Lyophilized preparation with cytotoxic dipeptides
EP2909690B1 (en) 2012-10-22 2017-07-19 Parker Hannifin Manufacturing Sweden AB Joystick for utility vehicles
SMT202000058T1 (it) * 2012-10-26 2020-03-13 Oncopeptides Ab Preparazioni liofilizzate di melfalan flufenammide
NZ713868A (en) * 2013-04-08 2021-12-24 Berg Llc Treatment of cancer using coenzyme q10 combination therapies

Also Published As

Publication number Publication date
NZ742548A (en) 2023-10-27
ZA202102438B (en) 2025-08-27
IL301019A (en) 2023-05-01
MX2021008738A (es) 2021-08-24
KR102279629B1 (ko) 2021-07-20
FI3383385T4 (fi) 2023-11-01
CY1123469T1 (el) 2022-03-24
AU2016363591B2 (en) 2020-12-10
EP3383385B1 (en) 2020-07-29
ES2828033T3 (es) 2021-05-25
LT3383385T (lt) 2020-12-28
PT3383385T (pt) 2020-10-26
SMT202000567T1 (it) 2020-11-10
DK3383385T3 (da) 2020-10-12
CA3003102C (en) 2022-09-13
CN108289876A (zh) 2018-07-17
MX2018006706A (es) 2018-08-01
US20220047507A1 (en) 2022-02-17
DK3383385T4 (da) 2023-11-06
ES2828033T5 (es) 2024-04-04
US20250144023A1 (en) 2025-05-08
AU2016363591A1 (en) 2018-06-28
EP3383385B2 (en) 2023-09-06
BR112018010012A2 (pt) 2018-11-21
RS60986B1 (sr) 2020-11-30
RU2734930C2 (ru) 2020-10-26
RS60986B2 (sr) 2023-12-29
EP3383385A1 (en) 2018-10-10
JP2019501881A (ja) 2019-01-24
CA3003102A1 (en) 2017-06-08
SG11201803551YA (en) 2018-05-30
EP3903777A1 (en) 2021-11-03
SI3383385T2 (sl) 2024-01-31
RU2018123718A (ru) 2020-01-09
BR112018010012A8 (pt) 2019-02-26
JP2021088560A (ja) 2021-06-10
AU2021200436A1 (en) 2021-02-25
WO2017093443A1 (en) 2017-06-08
IL301019B1 (en) 2025-08-01
SI3383385T1 (sl) 2020-11-30
IL301019B2 (en) 2025-12-01
JP6878431B2 (ja) 2021-05-26
KR20210092327A (ko) 2021-07-23
ZA201802816B (en) 2021-07-28
US20180369141A1 (en) 2018-12-27
HRP20201632T4 (hr) 2023-11-10
RU2020134307A (ru) 2020-11-27
EP3750534A1 (en) 2020-12-16
MX384724B (es) 2025-03-14
HUE051525T2 (hu) 2021-03-01
IL259101A (en) 2018-06-28
KR20180087254A (ko) 2018-08-01
HRP20201632T1 (hr) 2021-01-08
PL3383385T5 (pl) 2023-12-18
RU2018123718A3 (pl) 2020-04-02
GB201521217D0 (en) 2016-01-13

Similar Documents

Publication Publication Date Title
IL280863A (en) Autotaxin inhibitors and uses thereof
IL252126A0 (en) Methods for transduction and cell processing
PL3157552T3 (pl) Polipeptydy syntac i ich zastosowania
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
PL3653221T3 (pl) Przeciwciała anty-pvrig i sposoby ich zastosowania
LT3303334T (lt) Tirozinkinazės inhibitoriai
EP3754089C0 (de) Dosiereinrichtung
HUE053763T2 (hu) Immunellenõrzésipont-gátlók véreredetû rákok kezelésében történõ alkalmazásra
PL3148579T3 (pl) Przeciwciała anty-gitr i sposoby ich zastosowania
EP3344400A4 (en) Three dimensional microtissue bioprinter
DK3094351T3 (da) Immunmodulatoriske midler
DK3215153T3 (da) Immunregulatoriske midler
EP3183255C0 (en) SPIROPYRROLIDINES USEFUL AS MDM2 INHIBITORS
PL3383385T3 (pl) Schematy dawkowania melflufenu w nowotworze złośliwym
DK3182962T3 (da) Compositions and uses of amidine derivatives
IL258525A (en) Dosing regimens
EP3344595A4 (en) BLASTING AGENT
DK3094322T3 (da) Administration af tasimelteon i fastende tilstand
ES1162584Y (es) Aparato dosificador
PL3337506T3 (pl) Kombinacje i ich zastosowania
IL255560B (en) Macropinocytosis in cancer
PL3126791T3 (pl) Urządzenie do dozowania
HUE056161T2 (hu) Többfázisú készítmények
EP3137649C0 (en) METALLIZATION OF SURFACES
EP2986625A4 (en) MIXED MODE LIGANDS